Oncology Institute, Inc.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash and cash equivalents $25k $917k $115.2m $14.0m $33.5m $49.7m $33.6m
Accounts receivable, net $17.1m $20.0m $39.8m $42.4m $48.3m $59.0m
Other receivables $113k $1.2m $617k $551k $346k $322k
Inventories $4.4m $6.4m $9.3m $13.7m $10.0m $16.9m
Prepaid expenses and other current assets $6.9m $4.0m $4.0m $3.0m
Total current assets $25k $1.1m $154.1m $130.4m $143.5m $112.4m $112.7m
Property and equipment, net $2.1m $4.2m $8.5m $10.9m $11.9m $10.7m
Intangible assets, net $19.5m $18.2m $18.0m $17.9m $14.8m $11.0m
Goodwill $14.2m $26.6m $21.4m $7.2m $7.2m $7.2m
Operating right of use assets $0 $24.5m $29.2m $25.8m $22.4m
Other assets $122k $320k $477k $561k $589k $606k
Current portion of operating lease liabilities $0 $5.5m $6.4m $6.8m $7.2m
Accrued expenses and other current liabilities $26k $50k $13.9m $14.6m $14.0m $21.1m $20.6m
Operating lease liabilities $0 $22.1m $26.5m $23.2m $19.1m
Derivative warrant liabilities $0 $2.2m $350k $636k $17k $264k
Conversion option derivative liabilities $0 $60.0m $4.0m $3.1m $385k $12.6m
Other non-current liabilities $807k $6.9m $868k $365k $125k $28k
Total stockholders’ equity (deficit) $23k $5.0m $104.2m $123.2m $57.0m $3.6m ($15.7m)
Total assets $50k $231.3m $203.4m $261.7m $209.2m $172.7m $164.7m
Total liabilities and stockholders’ equity (deficit) $50k $231.3m $203.4m $261.7m $209.2m $172.7m $164.7m
Accounts payable $12.6m $15.6m $9.4m $14.4m $24.3m $43.2m
Total current liabilities $27k $268k $29.8m $29.7m $34.8m $52.2m $71.0m
Long-term debt, net of unamortized debt issuance costs $6.6m $0 $80.6m $86.8m $93.1m $77.4m
Deferred income taxes liability $1.6m $371k $108k $32k $32k $0
Total liabilities $27k $6.6m $99.3m $138.5m $152.2m $169.1m $180.4m
Commitments and contingencies (Note 15) $0 $0 $0 $0 $0 $0
Common Stock, 0.0001 par value, authorized 500,000,000 shares; 100,596,918 shares issued and 98,863,144 shares outstanding at December 31, 2025 and 77,470,886 shares issued and 75,737,112 shares outstanding at December 31, 2024 575 677 7k 7k 8k 8k 10k
Series A Convertible Preferred Stock, 0.0001 par value, authorized 10,000,000 shares; 193,507 and 165,045 shares issued and outstanding at December 31, 2025 and 2024, respectively 0 0 0 0 0 0
Additional paid-in capital $24k $5.4m $167.4m $186.2m $204.2m $215.4m $256.7m
Treasury Stock at cost, 1,733,774 shares at December 31, 2025 and 2024 $0 ($1.0m) ($1.0m) ($1.0m)
Accumulated deficit ($2k) ($443k) ($63.2m) ($63.1m) ($146.2m) ($210.8m) ($271.4m)